Imaging scans to detect amyloid deposits in people with amyloid-related disease
Tests PET/CT imaging scans to help detect amyloid deposits in adults with amyloidosis.
Plain-language title generated from the registry record
Registry title: Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Key facts
- Where
- Hefei, Qingdao, and Tianjin, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected, newly diagnosed or previously treated cardiac amyloidosis who have a Pan-Amyloid PET/CT scan planned.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Suspected, newly diagnosed or previously treated cardiac amyloidosis. Supporting evidence may include MRI, CT, blood markers and a pathology report.
Main reasons for not taking part
- Lesions that are not cardiac amyloidosis
- Pregnancy
- Unable or unwilling to give written informed consent
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07130565, who can take part
Where in China
- The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaTaking people
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
- Tianjin Medical University General HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tianjin Medical University
- Trial code
- NCT07130565
- Record updated
- 8 September 2026
- Original description
To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.Read full original descriptionShow less
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.
Inclusion: (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated cardiac amyloidosis (supporting evidence may include MRI, CT, serum markers and pathology report); (iii) patients who had scheduled Pan-Amyloid PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion: (i) patients with non-CA lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.